You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) Prophylaxis

Percentage of patients aged 6 weeks or older with a diagnosis of HIV/AIDS, who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis

Date Reviewed: July 26, 2014

Measure Info

NQF 0405CMS 160NQF EndorsedCQMC Core Measure
Measure Type: 
Process
Measure Steward: 
National Committee for Quality Assurance
Clinical Topic Area: 
HIV

Care Setting: 
Outpatient
Data Source: 
Other

ACP supports NQF 0405: “HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) Prophylaxis” because it aligns with current US Department of Health and Human Services guidelines for the prevention of opportunistic infections in those diagnosed HIV/AIDS.

As part of an ongoing effort to improve user experience, we have made some updates to the Performance Measures section of ACP. Tell us what you think!